Lene Sofie Granfeldt Østgård

Lene Sofie Granfeldt Østgård

Auto-generated profile, based on publicly available information

Lene Sofie Granfeldt Østgård

Department of Haematology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
BMBruno C. Medeiros
Bruno C. Medeiros
HSHenrik Sengeløv
Henrik Sengeløv
MNMette Nørgaard
Mette Nørgaard
MAMette Klarskov Andersen
Mette Klarskov Andersen
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
Purpose: Secondary and therapy-related acute myeloid leukemia (sAML and tAML, respectively) remain therapeutic challenges. Still, it is unclear whether their inferior outcome compared with de novo acute myeloid leukemia (AML) varies as a result of previous hematologic disease or can be explained by differences in karyotype and/or age. Patients and Methods: In a Danish national population-based study of 3,055 unselected patients with AML diagnosed from 2000 to 2013, we compared the frequencies and characteristics of tAML, myelodysplastic syndrome (MDS) -sAML, and non-MDS-sAML (chronic myelomonocytic leukemia and myeloproliferative neoplasia) versus de novo AML. Limited to intensive therapy patients, we compared chance of complete remission by logistic regression analysis and used a pseudo-value approach to compare relative risk (RR) of death at 90 days, 1 year, and 3 years, overall and stratified by age and karyotype. Results were given crude and adjusted with 95% CIs. Results: Overall, frequencies of sAML and tAML were 19.8% and 6.6%, respectively. sAML, but not tAML, was associated with low likelihood of receiving intensive treatment. Among intensive therapy patients (n = 1,567), antecedent myeloid disorder or prior cytotoxic exposure was associated with decreased complete remission rates and inferior survival (3-year adjusted RR for MDS-sAML, non-MDS-sAML, and tAML: RR, 1.14; 95% CI, 1.02 to 1.32; RR, 1.27; 95% CI, 1.16 to 1.34; and RR, 1.16; 95% CI, 1.03 to 1.32, respectively) compared with de novo AML. Among patients ≥ 60 years old and patients with adverse karyotype, previous MDS or tAML did not impact overall outcomes, whereas non-MDS-sAML was associated with inferior survival across age and cytogenetic risk groups (adverse risk cytogenetics: 1-year adjusted RR, 1.47; 95% CI, 1.23 to 1.76; patients ≥ 60 years old: 1-year adjusted RR, 1.31; 95% CI, 1.06 to 1.61). Conclusion: Our results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML. Patients with non-MDS-sAML have dismal outcomes, independent of age and cytogenetics. Previous myeloid disorder, age, and cytogenetics are crucial determinants of outcomes and should be integrated in treatment recommendations for these patients.

5 August 2014 in Leukemia
Verified
Journal Article
Closed access
PDF file
LØL S G Østgård
L S G Østgård
JNJ M Nørgaard
J M Nørgaard
HSH Sengeløv
H Sengeløv
MSMarianne Tang Severinsen
Marianne Tang Severinsen
LFL S Friis
L S Friis
MNM Nørgaard
M Nørgaard

1 September 2013 in Clinical Epidemiology
Verified
Journal Article
Open access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
MNMette Nørgaard
Mette Nørgaard
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
MSMarianne Tang Severinsen
Marianne Tang Severinsen
HSHenrik Sengeløv
Henrik Sengeløv
ONOve Juul Nielsen
Ove Juul Nielsen
Peer reviewed article authored by (Østgård LSG, Nørgaard JM, Severinsen MT, Sengeløv H, Friis L, Jensen MK, Nielsen OJ, Nørgaard M). Read article or submit your manuscript for publishing.

12 August 2010 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
EKEigil Kjeldsen
Eigil Kjeldsen
MHMette Skov Holm
Mette Skov Holm
PBPeter De Nully Brown
Peter De Nully Brown
BPBjarne Bach Pedersen
Bjarne Bach Pedersen
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard

10 November 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
MNMette Nørgaard
Mette Nørgaard
BMBruno C. Medeiros
Bruno C. Medeiros
LFLone Smidstrup Friis
Lone Smidstrup Friis
CSClaudia Schoellkopf
Claudia Schoellkopf
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
Purpose: Previous US studies have shown that socioeconomic status (SES) affects survival in acute myeloid leukemia (AML). However, no large study has investigated the association between education or income and clinical characteristics, treatment, and outcome in AML. Methods: To investigate the effects of education and income in a tax-supported health care system, we conducted a population-based study using individual-level SES and clinical data on all Danish patients with AML (2000 to 2014). We compared treatment intensity, allogeneic transplantation, and response rates by education and income level using logistic regression (odds ratios). We used Cox regression (hazard ratios [HRs]) to compare survival, adjusting for age, sex, SES, and clinical prognostic markers. Results: Of 2,992 patients, 1,588 (53.1%) received intensive chemotherapy. Compared with low-education patients, highly educated patients more often received allogeneic transplantation (16.3% v 8.7%). In intensively treated patients younger than 60 years of age, increased mortality was observed in those with lower and medium education (1-year survival, 66.7%; adjusted HR, 1.47; 95% CI, 1.11 to 1.93; and 1-year survival, 67.6%; adjusted HR, 1.55; CI, 1.21 to 1.98, respectively) compared with higher education (1-year survival, 76.9%). Over the study period, 5-year survival improvements were limited to high-education patients (from 39% to 58%), increasing the survival gap between groups. In older patients, low-education patients received less intensive therapy (30% v 48%; adjusted odds ratio, 0.65; CI, 0.44 to 0.98) compared with high-education patients; however, remission rates and survival were not affected in those intensively treated. Income was not associated with therapy intensity, likelihood of complete remission, or survival (high income: adjusted HR, 1.0; medium income: adjusted HR, 0.96; 95% CI, 0.82 to 1.12; low income: adjusted HR, 1.06; CI, .88 to 1.27). Conclusion: In a universal health care system, education level, but not income, affects transplantation rates and survival in younger patients with AML. Importantly, recent survival improvement has exclusively benefitted highly educated patients.

1 October 2016 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
KRKlas Kræsten Raaschou-Jensen
Klas Kræsten Raaschou-Jensen
RPRobert Schou Pedersen
Robert Schou Pedersen
DRDorthe Rønnov-Jessen
Dorthe Rønnov-Jessen
LFLone Smidstrup Friis
Lone Smidstrup Friis
Aim of database: The main aim of the Danish National Acute Leukemia Registry (DNLR) was to obtain information about the epidemiology of the hematologic cancers acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). Study population: The registry was established in January 2000 by the Danish Acute Leukemia Group and has been expanded over the years. It includes adult AML patients diagnosed in Denmark since 2000, ALL patients diagnosed since 2005, and MDS patients diagnosed since 2010. The coverage of leukemia patients exceeds 99%, and the coverage of MDS patients is currently 90%. Main variables and descriptive data: Approximately, 250 AML patients, 25 ALL patients, and 230 MDS patients are registered in the DNLR every year. In January 2015, the registry included detailed patient characteristics, disease characteristics, treatment characteristics, and outcome data on more than 3,500 AML, 300 ALL, and 1,100 MDS patients. Many of the included prognostic variables have been found to be of high quality including positive predictive values and completeness exceeding 90%. These variables have been used in prognostic observational studies in the last few years. To ensure this high coverage, completeness, and quality of data, linkage to the Danish Civil Registration System and the Danish National Registry of Patients, and several programmed data entry checks are used. Conclusion: The completeness and positive predictive values of the leukemia data have been found to be high. In recent years, the DNLR has shown to be an important high-quality resource for clinical prognostic research.